Aspirin for cancer prevention in individuals with Lynch syndrome: first results from the CaPP3 multicentre, randomised, double-blind, non-inferiority trial

Study limitation reported by the research below: “UK open-label phase used 75 mg instead of 100 mg aspirin, introducing a minor dose inconsistency across countries in the unblinded period.”